Statin use and risk of basal cell carcinoma.
Statin use and risk of basal cell carcinoma.
复制标题
DOI：
10.1016/j.jaad.2009.02.011
复制
发表时间：
2009-07
影响因子：
13.8
通讯作者：
Friedman, Gary D.
中科院分区：
文献类型：
--
作者：
Asgari, Maryam A.;Tang, Jean;Epstein, Ervin H., Jr.;Chren, Mary-Margaret;Warton, E. Margaret;Quesenberry, Charles P., Jr.;Go, Alan S.;Friedman, Gary D.
我们研究了他汀类药物的使用与基底细胞癌 (BCC) 风险之间的关联。我们确定了 1997 年诊断出患有经组织学证实的 BCC 的大型综合医疗服务系统的所有成员。随后的 BCC 是在 2006 年从健康计划电子病理记录中确定的。他汀类药物和其他降脂剂的纵向暴露是根据自动药房记录确定的。我们使用扩展 Cox 回归来检查接受他汀类药物治疗（曾经与从未、累积持续时间）与随后发生 BCC 风险之间的独立关联。为了最大限度地减少适应症的混淆，我们根据国家指南对被认为有资格接受降脂治疗的个体子集进行了敏感性分析。在 12,123 名被诊断患有 BCC 且之前未接触过他汀类药物的会员中，有 6381 人在随访期间出现了 BCC。在调整年龄、性别和医疗保健利用率后，他汀类药物的使用（调整后的风险比 [aHR] 1.02，95% CI：0.92-1.12）或他汀类药物的累积持续时间（每年 aHR 1.02，95% CI：0.99-1.11）与随后的 BCC 无关。当分析仅限于符合开始他汀类药物治疗资格标准的个体子集时，风险估计没有明显变化。使用非他汀类降脂药与随后的 BCC 之间也没有显着关联（aHR 1.10，95% CI：0.76-1.58）。没有关于 BCC 风险因素的信息，例如阳光敏感性和阳光照射。在一大群 BCC 患者中，他汀类药物治疗与随后发生 BCC 的风险没有显着相关性。
We examined the association between statin use and basal cell carcinoma (BCC) risk. We identified all members of a large integrated healthcare delivery system diagnosed with a histologically-proven BCC in 1997. Subsequent BCCs were identified through 2006 from health plan electronic pathology records. Longitudinal exposure to statins and other lipid-lowering agents was determined from automated pharmacy records. We used extended Cox regression to examine the independent association between receipt of statin therapy (ever vs. never, cumulative duration) and risk of subsequent BCC. To minimize confounding by indication, we conducted sensitivity analyses in the subset of individuals considered eligible for lipid-lowering therapy based on national guidelines. Among 12,123 members diagnosed with BCC who had no prior statin exposure, 6381 developed a subsequent BCC during follow-up. Neither ever use of statins (adjusted hazard ratio [aHR] 1.02, 95% CI: 0.92-1.12) or cumulative duration of statin (aHR 1.02 per year, 95% CI: 0.99-1.11) was associated with subsequent BCC after adjustment for age, sex, and healthcare utilization. Risk estimates did not change appreciably when the analysis was limited to the subset of individuals who met eligibility criteria for initiating statin therapy. There was also no significant association between use of non-statin antilipemics and subsequent BCC (aHR 1.10, 95% CI: 0.76-1.58). No information was available for BCC risk factors, such as sun sensitivity and sun exposure. Among a large cohort of individuals with BCC, statin therapy was not significantly associated with risk of subsequent BCC.
登录
查看更多内容
影响因子：
120.7
作者：
KARAGAS, MR;STUKEL, TA;STERN, RS
通讯作者：
STERN, RS
DOI：
10.1016/s0190-9622(08)81509-5
发表时间：
1994-05-01
影响因子：
13.8
作者：
MILLER, DL;WEINSTOCK, MA
通讯作者：
WEINSTOCK, MA
影响因子：
120.7
作者：
Christenson, LJ;Borrowman, TA;Roenigk, RK
通讯作者：
Roenigk, RK
影响因子：
5.3
作者：
Hillyard, DZ;Cameron, AJM;Jardine, AG
通讯作者：
Jardine, AG
影响因子：
158.5
作者：
Rossebo, Anne B.;Pedersen, Terje R.;Willenheimer, Ronnie
通讯作者：
Willenheimer, Ronnie